the-bolar-exemption

RetroClipArt / Shutterstock.com

20 June 2014GenericsRafal Witek

The Bolar exemption: the need for agreement

In recent months, we’ve had the opportunity to analyse the final decisions of the courts in Poland and Germany on the Astellas v Polpharma case interpreting the range of the Bolar exemption in Europe (for earlier details of the case click here).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

How post-filing data rescued Novo Nordisk’s Ozempic patent in China

Astellas defends blockbuster cancer treatment patent

How to navigate patent term adjustment in China

‘It was like starting all over again’: Tobias Wuttke

‘This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute